Romidepsin (FK228, Depsipeptide)

目录号:S3020 别名: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。

规格 价格 库存 购买数量  
RMB 1285.83 现货
RMB 3910.79 现货
RMB 5710.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。
特性 Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外研究

Romidepsin抑制NSCLC细胞系生长,IC50范围从1.3 ng/mL到4.9 ng/mL。 Romidepsin可以降低Erlotinib对NSCLC细胞系的IC50值, 增加NSCLC细胞系对Erlotinib的敏感性[1]。Romidepsin处理72小时可以抑制6/6 人 NB 肿瘤细胞系的生长,而 NIH3T3细胞系并不受影响。 Romidepsin对于单拷贝或N-myc 多拷贝的NB细胞系以及含有正常或突变的p53 和含有Alk突变体的细胞系都有选择性的细胞毒性,这种毒性具有剂量依赖的特性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVGyMlUuOTVibl2= MmPFO|IhcA>? MUnpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NUjX[YljOjV5OUC5NFc>
U2932  MlvCR4VtdCCYaXHibYxqfHliQYPzZZk> NHrDdmUzNjVvMUWgcm0> NV3MenBZPzJiaB?= MWHpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh Mn3nNlU4QTB7MEe=
OCI-LY7 M1;C[mNmdGxiVnnhZoltcXS7IFHzd4F6 MkD5Nk42NTF3IH7N MYO3NkBp MnXibY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NFe4WoYzPTd7MEmwOy=>
Farage MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX7jeHpSOi53LUG1JI5O NH;TZog4OiCq M{fTdYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NXK1TmdwOjV5OUC5NFc>
LY7/EBV NFPVW4FE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmDTNk42NTF3IH7N NFzKdVA4OiCq NF;QWmlqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NIO2XVczPTd7MEmwOy=>
U2932/EBV NYDGc|dIS2WubDDWbYFjcWyrdImgRZN{[Xl? NHTGdIMzNjVvMUWgcm0> M2rLbVczKGh? M{DCTIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M3LO[|I2PzlyOUC3
HCT116 NHO4bnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP6OU02ODByIH7N MnXVNlQhcA>? MlPQSG1UVw>? M1rTeolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NHK1SJEzPTR7MkWxOS=>
ACH-2 NVqyeoxsTnWwY4Tpc44hSXO|YYm= MlTzNU06KG6P MU[yOEBp MkfJbY5lfWOnczDITXYuOSCHbo[g[ZhxemW|c3nvci=> M{n1SFI2OTR7NE[3
MCF-10A NGrlUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX5Z5dqUUN3ME2wMlE4yrFyLkCxJI5O M{ex[VI1QTV2OEW2
MCF-7 MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ju[GlEPTB;MT6xNOKyOC5{MDDuUS=> M3rOU|I1QTV2OEW2
SK-BR-3 M2S3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vxZWlEPTB;MT6wNOKyOC5|NTDuUS=> M2SxdVI1QTV2OEW2
MDA-MB-231 M3nyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf1XXNKUUN3ME2wMlY5yrFyLkG0JI5O NFzaNo4zPDl3NEi1Oi=>
PC3 NWfaXnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3hRplKSzVyPUGuOlXDuTBwM{Wgcm0> NFrPTGYzPDl3NEi1Oi=>
HCT116 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3MTHhKSzVyPUGuNFDDuTBwMECgcm0> NHLJeGIzPDl3NEi1Oi=>
HCT116-p21-/- M3jHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXYTWM2OD1zLkK2xtExNjN5IH7N NFfNNFEzPDl3NEi1Oi=>
S1 NIq5eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO4TWM2OD15Lk[3xtExNjJ7IH7N NEPoSXkzPDl3NEi1Oi=>
SW620 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDrXY1zUUN3ME2wMlk{yrFyLkK5JI5O NEC0SI4zPDl3NEi1Oi=>
LOX-IMVI MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwOEhCtVAvODNibl2= NXXMXW1XOjR7NUS4OVY>
UACC-62 NYPO[3RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rTbGlEPTB;MD61OuKyOC5zNjDuUS=> NHrmbnIzPDl3NEi1Oi=>
MDA-MB-435 M4naWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z3[mlEPTB;MD65NOKyOC5yNjDuUS=> MUeyOFk2PDh3Nh?=
SF-295 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjK[3VKSzVyPUCuPFjDuTBwMUWgcm0> MkLwNlQ6PTR6NU[=
A549 M1Hx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fSc2lEPTB;MT6yOuKyOC5{NDDuUS=> NY[zR3JrOjR7NUS4OVY>
H460 Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJwNUlCtVAvQDBibl2= NWP6Sm1{OjR7NUS4OVY>
EKVX MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj6d|FKSzVyPUGuN|PDuTBwM{Sgcm0> NVnubFZ2OjR7NUS4OVY>
H146 NH7DZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTQTWM2OD1yLkKyxtExNjB5IH7N Mn3INlQ6PTR6NU[=
H526 M2f5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMUZCtVAvODNibl2= NGPrd2IzPDl3NEi1Oi=>
HuT-78 NVHvc5lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rPS2lEPTB;MT63N:KyOC52NDDuUS=> MXqyOFk2PDh3Nh?=
HA NHP2[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T4flAvPjJ3LUGwcm0> MkTIOFghcA>? Mn;GbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MV[yOFc4OTVzMB?=
MS-275 MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrINVJWOC54MkWtNVBvVQ>? NV;xR5VHPDhiaB?= MmC1bY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> MV6yOFc4OTVzMB?=
CD4 T M3v1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonIOFghcA>? MoG4SWM2OD12LkZCtVEvOCCwTR?= MXGyOFczOjR3NB?=
CD4 T MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHlOFghcA>? M{fibGNEPTB;MUC3xtEyOjZibl2= M3L3UFI1PzJ{NEW0
CD4+ T NEnsOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfIcYJGSzVyPUOgcm0> Ml[3NlQ1QTVzMEW=
A549 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O1XFEx6oDVMUCwxsBvVQ>? NYTJbotmOjRxM{[vOFghcA>? NHv3c3ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= Mn3HNlQ1QDV5OUm=
JJN3 Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nyelI1NzR6IHi= M2j5T2VEPTB:MfMAjY5OQyB2OPMAjYg> MUeyOFA{ODF3MB?=
OPM-2 NWfpbYZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmyOE81QCCq NXfYOYpXTUN3MIO9NgKBkW6POzC0PQKBkWh? MnznNlQxOzBzNUC=
RPMI-8226 NEH6V25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlziNlQwPDhiaB?= M1jxNGVEPTC|PUGuPQKBkW6POzC0PQKBkWh? MmHoNlQxOzBzNUC=
U266 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr1d3pLOjRxNEigbC=> MXLFR|Uxez1zMPMAjY5OQyB2OPMAjYg> M2DXXVI1ODNyMUWw
CA46 NFXrR3RCeG:ydH;zbZMhSXO|YYm= NYHNRnV{PiCq NXzpbJFycW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NWP4NYpEOjN7Nk[xOlQ>
DG75 NUjFZYM2SXCxcITvd4l{KEG|c3H5 MYi2JIg> MUfpcoR2[2W|IH7vJIFxd3C2b4Ppdy=> MkPjNlM6PjZzNkS=
Ramos NXj6UnFiSXCxcITvd4l{KEG|c3H5 NIPWd2Y3KGh? NXnaZmI5cW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ MVSyN|k3PjF4NB?=
ST486 MmfzRZBweHSxc3nzJGF{e2G7 NUizUnlmPiCq NHrvRXJqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> MVSyN|k3PjF4NB?=
HuT78 MmTqRZBweHSxc3nzJGF{e2G7 MYWxM|ExNzFyMDDuUS=> NFu4Wm41QCCq M2LKbIlv\HWlZYOgZZBweHSxc3nzJIF1KDFibl2= NED4dlIzOzV|MkezNi=>
DpVp35 MkS4RZBweHSxc3nzJGF{e2G7 MnW3NU8yOC9zMECgcm0> NVLkUmxwPDhiaB?= NEiyc25qdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MXyyN|U{Ojd|Mh?=
DpVp50 NWrRUHlGSXCxcITvd4l{KEG|c3H5 NV76T5V4OS9zMD:xNFAhdk1? NWnMdFl4PDhiaB?= Mn74bY5lfWOnczDicJVvfCCjcH;weI9{cXN? Ml7nNlM2OzJ5M{K=
DpP75  M2\ZOWFxd3C2b4Ppd{BCe3OjeR?= NEPkdmIyNzFyL{GwNEBvVQ>? NEnQXIM1QCCq NGfNWnlqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= M3\hNlI{PTN{N{Oy
SKOV-3 NHL1[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH0WHFTOeLCk{Kwcm0> M2H3VlczKGh? MnrXSG1UVw>? MVry[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MlHFNlMxOTB|NEi=
Brca1 WT Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfhe5oy6oDVMkDuUS=> MmXMO|IhcA>? NGnEOmVFVVOR NIHC[VZz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? Mo\zNlMxOTB|NEi=
Brca1 Null MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnUT4xwOeLCk{Kwcm0> M2fuTVczKGh? NG[4c2lFVVOR MXny[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> M2HvXVI{ODFyM{S4
OVCAR-8  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjiTmcy6oDVMkDuUS=> M1TEdVczKGh? Mm\QSG1UVw>? MVHy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MnP3NlMxOTB|NEi=
NCI/ADR-RES MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[0NgKBmzJybl2= MlH2O|IhcA>? M3vlfWROW09? MVvy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> NILoNVkzOzBzMEO0PC=>
HCT116 M2q5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTtdo45PSCwTT21NEDPxE1? MYSyOEBp MoDGSG1UVw>? NIPJ[GpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M3zjbVIzQTJ2OUW4
RKO M3\VPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUK1JI5ONTVyIN88US=> NVzy[oR{OjRiaB?= Ml7JSG1UVw>? M4jv[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NYHvVWV{OjJ7MkS5OVg>
CO115 M1XqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUeyTnp1PSCwTT21NEDPxE1? NVKyOGhlOjRiaB?= Mn\hSG1UVw>? M2Lqc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NGO4eJMzOjl{NEm1PC=>
HFS NYrEUm5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTtZno4PSCwTR?= M3ize|I1NzR6L{eyJIg> MonLbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NV3KWnB7OjJzME[yPFI>
LNCaP M1TiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi1JI5O NV73S2lPOjRxNEivO|IhcA>? MmXwbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NFjXS2ozOjFyNkK4Ni=>
A549 NIj1fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHIOUBvVQ>? MXqyOE81QC95MjDo M3rVRolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> M3jsbVIzOTB4Mkiy
697  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HPV2lEPTEkgJm95qCKOi53wrDuUS=> MnXUNlE2Ozh{MU[=
697-R M16yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|Ux6oDLPfMAjVgvPsLibl5CpC=> MUeyNVU{QDJzNh?=
HUT78 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rjVGlEPTB;MTDuUS=> NXfNXZVpOjFzOUi1OFU>
THJ-16T NHnrNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvnNUBvVQ>? MkG2NlQhcA>? M2jM[IlvcGmkaYTzJINmdGxiZ4Lve5Rp MU[yNFgyODV4OB?=
HCT116 M17lbmZ2dmO2aX;uJGF{e2G7 NXjwe3ZPOjBibl2= NVfybmY6QCCq MYPtc4R2dGG2ZYOgeJJidnOlcnnweEBt\X[nbIOg[o9zKGi3bnTy[YR{KG:oIHflcoV{KGmwIHXpeIhmeiCmaYLlZ5Rqd25? MnHvNlA4Ozl2NUS=
B104  M3HvOWZ2dmO2aX;uJGF{e2G7 MViyJI5O MVGyOE81QC95MjDo NFf6VpBqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= Mn;VNlA3QDZ3MEW=
HL-60  NVvaS3ZwS3m2b4TvfIlkcXS7IFHzd4F6 Mn6xNU02ODBibl2= NGnyOG0zPCCq MkXSbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MmHzNlA3OjRzNkO=
HP100 MlzaR5l1d3SxeHnjbZR6KEG|c3H5 NIHENnEyNTVyMDDuUS=> NHPuTY8zPCCq NVryXHlIcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NIixeoYzODZ{NEG2Ny=>
HL-60  M3;4fGZ2dmO2aX;uJGF{e2G7 NXPubGJFOTBibl2= NV\xNY1KPC94L{G2JIg> M{fUb4lv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= M4XWPVIxPjJ2MU[z
HP100 NGDnPIhHfW6ldHnvckBCe3OjeR?= MVuxNEBvVQ>? NELnN5I1NzZxMU[gbC=> MmfvbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq Mkm5NlA3OjRzNkO=
HL-60  Ml:1SpVv[3Srb36gRZN{[Xl? NIfLN4gyOC13MECgcm0> NVvJb2d{PCCq MVvk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? NEL0TGIzODZ{NEG2Ny=>
HP100 NHO5bGNHfW6ldHnvckBCe3OjeR?= NGjEV3YyOC13MECgcm0> MonBOEBp M1\QXIRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NVjvNXRbOjB4MkSxOlM>
11z NHPkS5lMcW6jc3WgRZN{[Xl? M4\5RVMuOTByIH7N NIe5NY1z\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= NYnsOGM4OjB4MEWxOFQ>
SKOV-3 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWW0M|gwOTZibl2= MX[0PEBp M3\DUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz Mo\PNlA1ODR3NkS=
OVCAR-3 NEnRbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXe0M|gwOTZibl2= NFy2TFM1QCCq NGLRb4dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NEXjWFMzODRyNEW2OC=>
HBL-2 MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCyMVExKG6P NELiWZczPCCq NX60XXRHUUN3ME20MlMhdk1? NFPFeG8zODB4OEC4NC=>
Jeko-1 NWTL[VVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zIOFIuPTBibl2= M{noOVI1KGh? M2rQO2lEPTB;MUGgcm0> NXXZfXR1OjByNkiwPFA>
Granta-519 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK1OU01OCCwTR?= NX63NXZQOjRiaB?= NU\0PIhXUUN3ME21PE42KG6P NHiwXHgzODB4OEC4NC=>
L1236 NUGy[3k3S3m2b4TvfIlkcXS7IFHzd4F6 MXSxJI5ONTFyMDFOwG0> M4ftblQ5KGh? NIHkUoZGSzVyPUCuNFch|ryP MWGxPVI{OzR5MB?=
L428 MU\DfZRwfG:6aXPpeJkhSXO|YYm= NIH4S|QyKG6PLUGwNEDPxE1? M3m4OVQ5KGh? MkPwSWM2OD1yLkSzJO69VQ>? MVixPVI{OzR5MB?=
KM-H2 NFjje2lEgXSxdH;4bYNqfHliQYPzZZk> MYOxJI5ONTFyMDFOwG0> NE\jb2k1QCCq NHf4bINGSzVyPUCuOVgh|ryP NHHNNHoyQTJ|M{S3NC=>
L540Cy MlPLR5l1d3SxeHnjbZR6KEG|c3H5 MlLTNUBvVS1zMECg{txO NIfBNZI1QCCq MoLMSWM2OD1yLkG2JO69VQ>? Mk\2NVkzOzN2N{C=
G401 NEPhN2ZHfW6ldHnvckBCe3OjeR?= NXTGU2JDOTBibl2= NFXQeYczPC92OD:3NkBp NHjRc3JFVVOR M{XzT4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MXSxPVIzOTV6Nh?=
STM91-01 M2q2VmZ2dmO2aX;uJGF{e2G7 NHu0ZY4yOCCwTR?= MX:yOE81QC95MjDo MYXEUXNQ MoHpbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MkjQNVkzOjF3OE[=
SJSC  MlP5SpVv[3Srb36gRZN{[Xl? MXKxNEBvVQ>? NFPlVm8zPC92OD:3NkBp Ml7GSG1UVw>? NFjyNlRqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> M4i4TlE6OjJzNUi2
BT16  MUnGeY5kfGmxbjDBd5NigQ>? M1rVPVExKG6P MV:yOE81QC95MjDo MmTuSG1UVw>? M13jV4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NWXNVmNbOTl{MkG1PFY>
NCI-H1299 M1vXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTVTWM2OD12LkdCtVAvOiCwZz;tcC=> MnTCNVkyPzl6OUC=
NCI-2882 M120bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHtTWM2OD1zLkdCtVAvODRibnevcYw> M{\XNVE6OTd7OEmw
HCC95 M3Ty[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXWTWM2OD1{LkZCtVAvODVibnevcYw> MmDRNVkyPzl6OUC=
NCI-H23 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XmfGlEPTB;Mj65xtExNjJibnevcYw> MVyxPVE4QTh7MB?=
NCI-H157 MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjhTWM2OD1zLkdCtVAvODJibnevcYw> MV[xPVE4QTh7MB?=
NCI-H460 M3rHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnPTWM2OD1{LkJCtVAvODdibnevcYw> MVSxPVE4QTh7MB?=
NCI-H1975 NYnyenRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCyTWM2OD1zLkRCtVAvODRibnevcYw> NGXqOJUyQTF5OUi5NC=>
NCI-H820 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJwNNMxNE4yKG6pL33s NV[2dnFFOTlzN{m4PVA>
NCI-H1650 M1HnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjDOnk2UUN3ME20MlnDuTBwMzDu[{9udA>? Mmr0NVkyPzl6OUC=
DTC1 NUDtS2tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNUGgcm0> M3S5Z|E5PTZ4MkS2
KAO MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\heW9LUUN3ME2wMlkyKG6P NGX6ZlEyQDV4NkK0Oi=>
SU-CCS-1 NYX2PXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:xTWM2OD1yLki5JI5O NX[zcoVrOTh3Nk[yOFY>
SYO-1 NH:w[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwNkegcm0> M1TXdVE5PTZ4MkS2
FUJI NGTVUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PhfWlEPTB;MT6zNUBvVQ>? NF2xeGkyQDV4NkK0Oi=>
SKNMC M13SUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwMUegcm0> NX\J[GFGOTh3Nk[yOFY>
402-91 NXzjcndTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwMk[gcm0> NWDWbJhWOTh3Nk[yOFY>
1765-92 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGxXm5KSzVyPUGuO|chdk1? M2joNFE5PTZ4MkS2
JN-DSRCT-1 NWLwSHZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf4VlNMUUN3ME2xMlI2KG6P NFjJTlIyQDV4NkK0Oi=>
NMS-2PC NFnpdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwOEGgcm0> MnG4NVg2PjZ{NE[=
HL60 M2mwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rDSmlEPTB;MT64OkBvVQ>? MV[xPFU3PjJ2Nh?=
A549 NI\I[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KySWlEPTB;Mz6yOEBvVQ>? Ml\VNVg2PjZ{NE[=
SW480 NULmbI1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHsSVlKSzVyPUKuOlkhdk1? M33OVlE5PTZ4MkS2
MCF7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X0UGlEPTB;Mz61OUBvVQ>? MWqxPFU3PjJ2Nh?=
PC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTKTWM2OD1{LkWxJI5O NFzXVokyQDV4NkK0Oi=>
MMRU NFrTWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;iUlNUUUN3ME2yMlU4KG6P NGLFeYQyQDV4NkK0Oi=>
Hs68 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRT5zMDDuUS=> M3K4SlE5PTZ4MkS2
hMSC-001F M1zifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHIepVQUUN3ME2+NVAhdk1? MlHYNVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

体内研究 与PBS处理的对照组相比,单独使用Erlotinib 和 Romidepsin分别可以对NCI-H1299细胞系的异种移植生长抑制到72% 和 43% ,但是并不具有明显的统计学意义。只有当两种药物联用的时候才会对其生长造成明显的抑制作用,此时生长被抑制到28% [1]。在免疫功能低下的小鼠中,Romidepsin 会抑制皮下NB 异种移植的生长,这种抑制作用具有剂量依赖的特性 。此外, 在NB病人的肿瘤组织中Romidepsin 会诱导某些基因的表达,如 p21 和p75 以及NTRK (TrkA) [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
细胞实验:[3]
+ 展开
  • Cell lines: NCI-H1975, NCI-H157, NCI-2882, NCI-H460 和 HCC95 细胞系
  • Concentrations: 1 ng/mL
  • Incubation Time: 72 小时
  • Method: 使用MTS法分析药物敏感性。在96孔平板中每孔接种2×103个细胞(包括NCI-H1975, NCI-H157, NCI-2882, NCI-H460和HCC95) 。24小时后, 在存在或者缺少1 ng/mL Romidepsin的条件下将细胞与不同浓度 (0.01 µM - 250 µM) 的Erlotinib 37°C 孵育72 小时。 MTS 溶液加到每个孔中37°C孵育1小时。利用分光光度计测量490 nm 处的光密度值。每种药物浓度的实验都设置8个复孔并重复两次。基于细胞生存曲线的吸光度值计算药物的半抑制浓度 (IC50) 。
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带NCI-H1299 细胞的 BALB/c无胸腺裸小鼠
  • Formulation: 用PBS配制
  • Dosages: 1.2 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次加入纯溶剂:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 540.7
化学式

C24H36N4O6S2

CAS号 128517-07-7
稳定性 powder
别名 FR 901228, NSC 630176

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)供应商 | 采购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)价格 | Romidepsin (FK228, Depsipeptide)生产 | 订购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID